Inhibitory activities of baicalin against renin and angiotensin-converting enzyme

Pharmaceutical Biology

Volumn 50, Issue 4, 2012, Pages 401-406

  Deng, Y F ^a   Aluko, R E ^b   Jin, Q ^a   Zhang, Y ^a   Yuan, L J ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

ACE; Binding constant; Fluorescence quench; Quench constant

Indexed keywords

BAICALIN; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; IC 50; IN VITRO STUDY; MOLECULAR INTERACTION; PROTEIN INTERACTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BINDING SITES; CATALYTIC DOMAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; KINETICS; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT PROTEINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPECTROMETRY, FLUORESCENCE;

SCUTELLARIA BAICALENSIS;

EID: 84863230916     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2011.608076     Document Type: Article

References (28)

1. Black P, Wrapson C. (2001). ACE inhibitors for hypertension. N Z Med J, 114, 20-21. (Pubitemid 32125554)
2. Blatt E, Chatelier RC, Sawyer WH. (1986). Effects of quenching mechanism and type of quencher association on Stern-Volmer plots in compartmentalized systems. Biophys J, 50, 349-356.
3. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakof LR, Bard RH, Bühler FR. (1972). Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med, 286, 441-449.
4. China Pharmacopoeia Committee, Pharmacopoeia of the People's Republic of China, the frst division of 2010 ed., China Chemical Industry Press, Beijing, 1999, p. 282-283.
5. Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Menard J, Corvol P. (1985). Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem, 260, 9154-9157. (Pubitemid 15249892)
6. Cushman DW, Cheung HS. (1971). Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol, 20, 1637-1648.
7. Epps DE, Raub TJ, Caiolfa V, Chiari A, Zamai M. (1999). Determination of the afnity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fuorescence of the protein. J Pharm Pharmacol, 51, 41-48. (Pubitemid 29097267)
8. Graves JW. (2002). Additional side effects of ACE inhibitors. Am Fam Physician, 66, 2048. (Pubitemid 36133634)
9. Huang Y, Tsang SY, Yao X, Chen ZY. (2005). Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord, 5, 177-184. (Pubitemid 40645490)
10. Israili ZH, Hall WD. (1992). Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med, 117, 234-242.
11. Lin CC, Shieh DE. (1996). The anti-infammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med, 24, 31-36.
12. Lynch KR, Peach MJ. (1991). Molecular biology of angiotensinogen. Hypertension, 17, 263-269.
13. Maibaum J, Feldman DL. (2003). Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ter Pat, 13, 589-603. (Pubitemid 36622214)
14. Morice AH, Brown MJ, Higenbottam T. (1989). Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol, 13 Suppl 3, S59-S62. (Pubitemid 19172490)
15. Peach MJ. (1977). Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev, 57, 313-370. (Pubitemid 8097628)
16. Quay SC, Heropoulos A, Commes K, Dzau VJ. (1985). Probing the renin active site by collisional quenching of endogenous fuorescence. J Biol Chem, 260, 15055-15058. (Pubitemid 16147991)
17. Remková A, Remko M. (2010). The role of renin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res, 59, 13-23.
18. Sarver RW, Peevers J, Cody WL, Ciske FL, Dyer J, Emerson SD, Hagadorn JC, Holsworth DD, Jalaie M, Kaufman M, Mastronardi M, McConnell P, Powell NA, Quin J 3rd, Van Huis CA, Zhang E, Mochalkin I. (2007). Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal Biochem, 360, 30-40. (Pubitemid 44894351)
19. Shah RV, Desai AS, Givertz MM. (2010). The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. J Card Fail, 16, 260-267.
20. Sibanda BL, Blundell T, Hobart PM, Fogliano M, Bindra JS, Dominy BW, Chirgwin JM. (1984). Computer graphics modelling of human renin. Specifcity, catalytic activity and intron-exon junctions. FEBS Lett, 174, 102-111. (Pubitemid 14031176)
21. Stanton A. (2003). Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst, 4, 6-10. (Pubitemid 36443380)
22. Stanton A, Jensen C, Nussberger J, O'Brien E. (2003). Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42, 1137-1143. (Pubitemid 37549068)
23. Takizawa H, DelliPizzi AM, Nasjletti A. (1998). Prostaglandin I2 contributes to the vasodepressor effect of baicalein in hypertensive rats. Hypertension, 31, 866-871. (Pubitemid 28108589)
24. Wang GT, Chung CC, Holzman TF, Kraft GA. (1993). A continuous fuorescence assay of renin activity. Anal Biochem, 210, 351-359. (Pubitemid 23171029)
25. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. (2003). Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun, 308, 698-705. (Pubitemid 36976519)
26. Yuan L, Wu J, Aluko RE, Ye X. (2006). Kinetics of renin inhibition by sodium houttuyfonate analogs. Biosci Biotechnol Biochem, 70, 2275-2280. (Pubitemid 44451907)
27. Yuan L, Wu J, Aluko RE. (2007). Size of the aliphatic chain of sodium houttuyfonate analogs determines their afnity for renin and angiotensin I converting enzyme. Int J Biol Macromol, 41, 274-280. (Pubitemid 46990529)
28. Zaman MA, Oparil S, Calhoun DA. (2002). Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov, 1, 621-636. (Pubitemid 37368827)